Back to search results

A Study of PF-08049820 for Moderate to Severe Eczema

This study is looking into whether a medicine called PF-08049820 is safe and effective for people with moderate to severe atopic dermatitis (AD), also known as eczema. People with AD often experience severe itching and rashes. We are seeking 165 participants, aged 18 to 64, who have had AD for at least six months and whose doctors consider their condition to be moderate to severe. You would take either PF-08049820 or a placebo (a tablet with no medicine) daily for 12 weeks. The main goal is to see how much your eczema symptoms improve by Week 12, measured by a score called the Eczema Area and Severity Index (EASI). The study status is currently unclear.

Study design
This interventional study plans to enroll 165 participants. Participants will receive either PF-08049820 or a placebo.
What's involved
You would take either PF-08049820 or a placebo tablet daily for 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at Week 12.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07216027

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

Recruiting
PHASE2Ages 18–64InterventionalTreatment
Pfizer
~165 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:PF-08049820Placebo

At a glance

Recruiting sites
16 of 20 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 12
Measured over Week 12

Conditions

Atopic Dermatitis
Eczema, Atopic

Explore related trials

Atopic Dermatitis

Where it's being run

20 sites across 10 states
New York5
California4
Florida2
Kanagawa2
Tokyo2
Pennsylvania1
Canada1
Shanghai Municipality1

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Affected body surface area (BSA) greater than or equal to 10% and up to 60%;
Validated Investigator's Global Assessment (vIGA) greater than or equal to 3;
Eczema Area and Severity Index (EASI) greater than or equal to 16;
Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit 4. Do not have a suitable prescribed medicine for AD. 5. Body Mass Index (BMI) of 18 to 38 kg/m2 and a total body weight greater than 48 kg (106 lbs)

What this trial measures

  • Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 12Week 12